Cbe, ma (Oxon), mbchB, bsc (Hons), msc, PhD, md, dsc, frcp (Glasgow,Edinburgh and London), frcgp (hon), fcanSci, fmedSci

Section 3: Gene Therapy

Akita N, Maruta F, Seymour L, Kerr DJ, Parker AL, Asai T, Oku N, Nakayama J and Miyagawa S. Identification of oligopeptides binding to peritoneal tumours of gastric cancer. Cancer Science. Vol 97 (1) 1075-1081. 2006

Palmer DH, Chen MJ, Kerr DJ. Taking Gene Therapy into the Clinic. Journal of Biomedicine and Biotechnology. 2003; 71-77.

Kerr, DJ, Seymour, LW, & Maruta. Gene Therapy for colorectal cancer. Expert Opinion Biol. (2003) 3 (5): 779-788
Kerr DJ. Clinical development of gene therapy for colorectal cancer. Nature Reviews Cancer, (2003) 3 615-622.
Palmer D H, Milner A E, Kerr D J and Young L S. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductaseCB1954, and identification of synergism with 5-fluorouracil. British Journal of Cancer (September 2003), Volume 89, Number 5, Pages 944-950
Knox RJ, Burke PJ, Chen S and Kerr DJ. CB 1954: From the Walker Tumor to NQO2 and VDEPT. Current Pharmaceutical Design, (2003), 9: 2091-2104
Palmer DH, Milner AE, Kerr DJ, Young LS. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.

Br J Cancer. 2003 Sep 1;89(5):944-50. Kerr DJ, Seymour LW, Maruta F. Gene therapy for colorectal cancer. Expert Opin Biol Ther. 2003 Aug;3(5):779-88.

Maruta F, Parker AL, Fisher KD, Murray PG, Kerr DJ, Seymour LW. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target. 2003 Jan;11(1):53-9.
Maruta,F; Parker,A.L; Fisher,K.D; Hallissey,M.T; Ismail,T; Rowlands,D.C; Chandler,L.A; Kerr,D.J; Seymour,L.W. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer-Gene-Ther. 2002 Jun; 9(6): 543-52
Palmer DH, Mautner V, Kerr DJ. Clinical experience with adenovirus in cancer therapy. Current Opinion in Molecular Therapeutics. 4(5): 423-434 (2002).
Chen, M.J., Chung-Faye, G.A., Searle, P.F., Young, L.S., and Kerr, D.J. (2001). Gene Therapy for colorectal cancer: therapeutic potential. BioDrugs 15, 357-67.

Chung-Faye, G., Palmer, D., Anderson, D., Baddeley, J., Hussain, S, Murray, P.I., Searle, P., Seymour, L., Harris, P.A., Ferry, D., And Kerr, D.J. (2001). Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7, 2662-8.

Djjeha, A.H., Hulme, A., Mountain, A., Young, L.S., Searle, P.F., Kerr, D.J., and Wrighton, C.M. (2000). Expression E.coli B nitroreductase in established human tumor xenografts in mice results in antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Therapy 7, 721 –731.

Weedon,S.J; Green,N.K; McNeish,I.A; Gilligan,M.G; Mautner,V; Wrighton,C.J; Mountain, A; Young,L.S; Kerr,D.J; Searle,P.F. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int-J-Cancer. 2000 Jun 15; 86(6): 848-54
Green, N.K., Weedon, S.J., McNeish, I.A., Mautner, V., Young, L.S., Kerr, D.J., and Searle, P.F. (1999). Gene Therapy for cancer: In vivo killing of tumour cells expressing E-coli nitroreductase following administration of the prodrug CB1954. Gene Therapy 6, 33.
Murray, P.G.,Billingham, L.J., Hassan, H.T., Flavell, J.R., Nelson, P.N., Scott, K., Reynolds, G., Constandinou, C.M., Kerr, D.J., Devey, E.C., Crocker, J., and Young, L.S. (1999). Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin’s disease. Blood 94, 442-447.

Grove JI, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus-directed enzyme prodrug therapy using CB1954. Anti-Cancer Drug Design, 14, 461-472 (1999)

Traunecker, H.C., Stevens, M.C.G., Kerr, D.J., and Ferry, D.R (1999). The acridonecarboxamide GF120918 potently reverses P-glycoprotein – mediated resistancein human sarcoma MES-Dx5 cells. British Journal of Cancer 81, 942-951.
Searle, P.F., Weedon, S.J., McNeish, I.A., Gilligan, M.G., Ford, M.J., Friedlos, F., Springer, C.J., Young, L.S., and Kerr, D.J. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E-coli nitroreductase gene. Advances in Experimental Medicine and Biology 451, 107-113. (1998).
Gilligan MG, Knox P, Weedon S, Barton R, Kerr DJ, Searle P and Young LS. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Therapy 5, 965-974 (1998)

Green NK, Gillian MG, Kerr DJ, Searle PF, Young LS. Gene therapy for cancer: prospects for the treatment of lung tumours. Molecular Biology of the Lung, Vol. 2, No 10: 183-201 (1998)

McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, Kerr DJ, and Searle PF. Virus directed enzyme prodrug therapy for ovarian and pancreatric cancer using retrovirally delivered E. Coli nitroreductase and CB1954. Gene Therapy 1998; 5.1061-9.

McNeish IA, Gilligan MG, Green NK, Roberts SM, Kerr DJ, Friedlos F, Springer CJ, and Searle PF. Virus-directed enzyme prodrug therapy using retrovirally delivered E. coli nitroreductase and CB1954. British Journal of Cancer 1998; 78.155-6.

Herod, JJO; Eliopoulos, AG; Warwick, J; Niedobitek, G; Young, LS; Kerr, DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184. (1996)

Thompson, AM; Steel, CM; Foster, ME; Kerr, D; Paterson, D; Deane, D; Hawkins, RA; Carter, DC; Evans, HJ Gene expression in oestrogen-dependant human breast cancer xenograft tumours. Br J Cancer 62: 78-84. 1990